Keep pulling the thread on Mark Zuckerberg & Priscilla Chan.
The Chan Zuckerberg Initiative acquired Evolutionary Scale, the creators of the protein model ESM3.
Alex Rivas, CEO of Evolutionary Scale, has been appointed to lead the combined AI and biology program at the Chan Zuckerberg Initiative.
The Chan Zuckerberg Initiative has a roadmap to develop a virtual cell capable of simulating biological responses in silico.
For its next phase, the Chan Zuckerberg Initiative will make science its main focus, specifically through the Biohub organization.
The Chan Zuckerberg Initiative is currently undertaking a "billion cell project" that is proceeding in months and at a fraction of the cost of earlier cell atlas work.
The core strategy of the Biohub is to conduct frontier biology and frontier AI research in sync, designing biological tools specifically to collect data for new AI models.
The New York Biohub is conducting cellular engineering research to create cells that can diagnose plaques in a person's heart and report the signal as cell-free DNA.
The Chan Zuckerberg Initiative's strategy is to address an underfunded area in science: tool development, which often requires a 10 to 15-year runway and hundreds of millions of dollars.
The first Biohub established by the Chan Zuckerberg Initiative was a collaboration between Stanford University, UCSF, and UC Berkeley.
The Chan Zuckerberg Initiative has compiled one of the largest corpuses of RNA transcriptomes, containing 125 million cells.
The Chan Zuckerberg Initiative was likely the first organization to build a large-scale compute cluster specifically for biological research.
Mark Zuckerberg envisions merging various virtual cell models into a single "biological omni model" to achieve positive transfer and stronger overall capabilities.